Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TAK, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Vedolizumab FDA approved May 2014 · Entyvio |
Crohn's Disease | Phase 4 · NCT06045754 | Active not recruiting |
| Mobocertinib (TAK-788) FDA approved Sep 2021 · Exkivity (discontinued) |
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 3 · NCT04129502 | Completed |
| Vortioxetine FDA approved Sep 2013 · Trintellix |
Major Depressive Disorder | Phase 3 · NCT07204314 | Recruiting |
| Ponatinib FDA approved Dec 2012 · Iclusig |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 · NCT03263572 | Recruiting |
| Brigatinib FDA approved Apr 2017 · Alunbrig |
Neurofibromatosis Type 2 | Phase 2 · NCT04374305 | Recruiting |
| Ixazomib FDA approved Nov 2015 · Ninlaro |
HIV (Human Immunodeficiency Virus) | Phase 2 · NCT07881809 | Not yet recruiting |
| Maribavir FDA approved Nov 2021 · Livtencity |
Cytomegalovirus (CMV) | N/A · NCT06555432 | Recruiting |
| TAK-360 | Idiopathic Hypersomnia | Phase 2/3 · NCT07646678 | Recruiting |
| TAK-279 | Generalized Pustular Psoriasis | Phase 3 · NCT06323356 | Completed |
| TAK-861 | Narcolepsy Type 1 (NT1) | Phase 3 · NCT07363720 | Active not recruiting |
| Mezagitamab | Immune Thrombocytopenic Purpura (ITP) | Phase 3 · NCT06948318 | Recruiting |
| Eptacog Alfa | Hemophilia A | Phase 3 · NCT04563520 | Withdrawn |
| Anti-Inhibitor Coagulant Complex | Hemophilia A | Phase 3 · NCT04563520 | Withdrawn |
| Fazirsiran | Alpha1-Antitrypsin Deficiency | Phase 3 · NCT05899673 | Active not recruiting |
| Elritercept | Myelodysplastic Syndrome | Phase 3 · NCT07422480 | Recruiting |
| TAK-928 | IO Resistant Squamous and Nonsquamous NSCLC | Phase 3 · NCT07217301 | Recruiting |
Also used in these trials (approved or third-party drugs, not TAK's own candidates): Adalimumab, Tofacitinib, Ustekinumab, Pemetrexed Disodium, Emicizumab, Epoetin Alfa, Cisplatin, Carboplatin, Retifanlimab, Bevacizumab, Blinatumomab, Brentuximab Vedotin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TAK holds $418.5B in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TAK files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited | 5%+ holder (13G) | 8,781,996 | 0.56% | 2025-12-08 |
| Andrew Stewart Plump President, R&D, Director |
Insider | 912,034 | 0.06% | 2026-09-02 |
| Julie So-Young Kim President and CEO, Director |
Insider | 391,489 | 0.03% | 2026-08-10 |
| Giles Richard Platford President, IBU |
Insider | 270,253 | 0.02% | 2026-11-04 |
| Teresa Marie Bitetti President, OBU |
Insider | 214,501 | 0.01% | 2026-11-02 |
| Natalie Anne Marie Furney Global General Counsel |
Insider | 204,298 | 0.01% | 2026-08-10 |
| Lauren Rusckowski Duprey Chief Transformation Officer |
Insider | 191,522 | 0.01% | 2026-09-14 |
| Rhonda Janice Pacheco President, U.S. Business Unit |
Insider | 182,507 | 0.01% | 2026-08-10 |
| Agosti Marcello Pignagnoli Head, Strat. & Port. Dev |
Insider | 176,977 | 0.01% | 2026-08-10 |
| Gabriele Ricci Chief Data & Tech. Officer |
Insider | 171,654 | 0.01% | 2026-08-10 |
| Awny Samaan Botros Farajallah Chief Medical Officer |
Insider | 116,177 | 0.01% | 2026-08-10 |
| Ramy Riad Ahmed Ibrahim President, PDT BU |
Insider | 102,588 | 0.01% | 2026-08-10 |
Share count 1,557,765,596 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TAK and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →